先声药业(02096)早盘上涨6.45%,现报7.43港元,成交额5049.47万港元。
先声药业发布公告,2024年12月1日,先必新舌下片(依达拉奉右莰醇舌下片)获中国国家药品监督管理局(NMPA)批准在中国上市,用于改善急性缺血性脑卒中(“AIS”)所致的神经症状、日常生活活动能力和功能障碍。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.